Kernal Biologics

Emerging

AI-designed mRNA 2.0 therapeutics for in vivo CAR-T cancer and autoimmune therapy; $35.8M raised with Amgen Ventures backing advancing KR-335 toward IND filing.

Updated March 2026

Company Overview

About Kernal Biologics

Kernal Biologics is a clinical-stage biotech developing AI-designed mRNA therapeutics for cancer and autoimmune diseases — using machine learning to engineer cell-type-specific mRNA sequences that direct therapeutic payloads (including CAR-T gene programs) to the right cells in vivo, enabling off-the-shelf CAR-T cancer therapy without the individualized cell extraction and ex vivo manufacturing process that makes current CAR-T treatments cost $400,000+ and require weeks of production time. The Y Combinator-backed company has raised $35.8 million including a $25 million Series A led by Hummingbird Ventures with participation from Amgen Ventures.

Business Model & Competitive Advantage

Kernal's platform analyzes transcriptome data to identify cell-type-specific RNA regulatory elements — promoters, UTRs, and expression signals that direct which cell types will take up and express a given mRNA. By engineering these regulatory elements using ML-guided design, Kernal can create mRNA constructs that preferentially express in specific cell populations (T cells, B cells, macrophages) after systemic delivery, enabling CAR-T programs to work without ex vivo cell collection. The lead program KR-335 is advancing toward IND filing for immuno-oncology indication.

Competitive Landscape 2025–2026

In 2025, Kernal competes in the mRNA therapeutics and cell therapy market with Moderna, BioNTech, and In Vivo Therapeutics for next-generation mRNA platforms, and with Beam Therapeutics, Prime Medicine, and other ex vivo CAR-T developers for the oncology and autoimmune indication space. The promise of in vivo CAR-T — delivering a gene therapy injection that programs the patient's own immune cells to fight cancer — represents a potential transformation of a $20B+ CAR-T market by eliminating the manufacturing complexity. Amgen Ventures' participation signals pharma interest in next-generation cell therapy platforms. The 2025 strategy focuses on advancing KR-335 toward clinical trials, building the mRNA design platform evidence base, and exploring partnership opportunities with larger biopharma companies for CAR-T and autoimmune indications.

Revenue
$35.8M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Kernal Biologics is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

YouShift

Healthcare Tech
HealthtechManufacturing

YouShift is a United States-based AI healthcare workforce management platform — building the operating system for healthcare staffing starting with AI-powered scheduling agents that replace the comple

Decoda Health

Healthcare
HealthtechAi PoweredAutomationNorth America

Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap

Abacum

Finance
B2bSaasAnalyticsAi PoweredFintechAutomation

Abacum is an FP&A (Financial Planning and Analysis) automation platform helping finance teams at growth-stage companies build automated financial models, track KPIs in real time, and collaborate on bu

Uncommon Therapeutics

Healthcare
Healthtech

Uncommon Therapeutics is a biotech company founded by Noah Auerhahn — directly inspired by his daughter's diagnosis with Rett Syndrome, a severe genetic neurological disease affecting approximately 1

Compare Kernal Biologics with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Kernal Biologics

Claim This Profile

Are you from Kernal Biologics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Kernal Biologics Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Kernal Biologics vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →